{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:39:58Z","timestamp":1775075998320,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":5026,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1097\/igc.0b013e3182126f05","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T07:19:04Z","timestamp":1300259944000},"page":"633-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum\/Taxane-Refractory\/Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers"],"prefix":"10.1016","volume":"21","author":[{"given":"Michael G.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Mor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Husband","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Azodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e3182126f05_bb0005","first-page":"99","article-title":"Current diagnosis and treatment modalities for ovarian cancer","volume":"107","author":"Schwartz","year":"2002","journal-title":"Cancer Treat Res."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0010","author":"American Cancer Society. Cancer Facts and Figures"},{"key":"10.1097\/IGC.0b013e3182126f05_bb0015","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/S0140-6736(03)13726-9","article-title":"Chemotherapy for recurrent ovarian cancer","volume":"361","author":"Kaye","year":"2003","journal-title":"Lancet."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0020","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/S0959-8049(02)00495-1","article-title":"Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate","volume":"38","author":"Engel","year":"2002","journal-title":"Eur J Cancer."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1634\/theoncologist.6-4-327","article-title":"Ovarian cancer","volume":"6","author":"Seiden","year":"2001","journal-title":"Oncologist."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568009033333754","article-title":"Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation","volume":"3","author":"Yusuf","year":"2003","journal-title":"Curr Cancer Drug Targets."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0035","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1124","article-title":"Rethinking clinical trials for cytostatic drugs","volume":"3","author":"Millar","year":"2003","journal-title":"Nat Rev Cancer."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0040","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat Rev Cancer."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/excr.2000.4838","article-title":"Induction of apoptosis by cancer chemotherapy","volume":"256","author":"Kaufmann","year":"2000","journal-title":"Exp Cell Res."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0050","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1189\/jlb.71.6.907","article-title":"Immune escape of tumors: apoptosis resistance and tumor counterattack","volume":"71","author":"Igney","year":"2002","journal-title":"J Leukoc Biol."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1477-7827-1-66","article-title":"Chemoresistance in human ovarian cancer: the role of apoptotic regulators","volume":"1","author":"Fraser","year":"2003","journal-title":"Reprod Biol Endocrinol."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0060","first-page":"567","article-title":"Resistance of ovarian cancer cells to docetaxel is XIAP dependent and reversible by phenoxodiol","volume":"14","author":"Sapi","year":"2004","journal-title":"Anticancer Drugs."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0065","first-page":"2200","article-title":"Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line","volume":"63","author":"Lamendola","year":"2003","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0070","doi-asserted-by":"crossref","unstructured":"Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 002;2:277\u2013288.","DOI":"10.1038\/nrc776"},{"key":"10.1097\/IGC.0b013e3182126f05_bb0075","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1038\/sj.onc.1206422","article-title":"PhenoxodiolVan isoflavone analogueVinduces apoptosis in chemo-resistant ovarian cancer cells","volume":"22","author":"Kamsteeg","year":"2003","journal-title":"Oncogene."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0080","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cncr.21633","article-title":"Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells","volume":"106","author":"Alvero","year":"2006","journal-title":"Cancer."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0085","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-04-2429","article-title":"Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1\/CIP1","volume":"65","author":"Aguero","year":"2005","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0090","first-page":"542","article-title":"Phenoxodiol, a novel approach for the treatment of ovarian cancer","volume":"7","author":"Mor","year":"2006","journal-title":"Curr Opin Investig Drugs."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0095","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdl010","article-title":"Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer","volume":"17","author":"Choueiri","year":"2006","journal-title":"Ann Oncol."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-006-0189-6","article-title":"Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer","volume":"58","author":"de Souza","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0105","first-page":"254","article-title":"Phenoxodiol phase Ib\/II study in patients with recurrent ovarian cancer that are resistant to Q second line chemotherapy","volume":"11","author":"Rutherford","year":"2004","journal-title":"J Soc Gynecol Investig."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0110","series-title":"Available at","article-title":"Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31","author":"Cancer Therapy Evaluation Program","year":"2003"},{"key":"10.1097\/IGC.0b013e3182126f05_bb0115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate response to treatment in solid tumours","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0120","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125","volume":"14","author":"Rustin","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182126f05_bb0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-111-4-273","article-title":"Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms","volume":"111","author":"McGuire","year":"1989","journal-title":"Ann Intern Med."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24038519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24038519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0b013e3182126f05","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:31:59Z","timestamp":1739503919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24038519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1048891X24038519"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e3182126f05","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum\/Taxane-Refractory\/Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e3182126f05","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}